Levofloxacin (Levofloxacin Hemihydrate)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes that unwind and separate DNA during replication. By inhibiting these enzymes, the drug prevents bacterial DNA synthesis, leading to cell death. This mechanism provides bactericidal activity against a wide range of Gram‑positive and Gram‑negative organisms.

The specific dose and duration of Levofloxacin therapy are determined by the prescribing clinician based on the infection type, severity, patient renal function, and local antimicrobial guidelines. Healthcare professionals should follow the recommended dosing regimen on the product label or institutional protocol.

Levofloxacin is classified as pregnancy category unknown, and its safety in pregnant or nursing women has not been established. Clinicians should weigh potential benefits against risks and consider alternative agents when treating pregnant or lactating patients.

To request Levofloxacin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Levofloxacin is a third‑generation fluoroquinolone with enhanced activity against Gram‑negative pathogens and a once‑daily dosing option for many indications. Compared with older agents like ciprofloxacin, it often provides broader coverage of respiratory pathogens and may achieve higher tissue concentrations, but safety considerations such as tendon toxicity remain similar across the class.

Levofloxacin intravenous solution should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from excessive moisture, direct sunlight, and extreme temperature fluctuations to maintain stability and potency.

Levofloxacin is supplied as an intravenous solution and is administered by slow infusion into a vein, typically over 30‑60 minutes. The infusion rate and dilution volume are determined by the prescribing clinician and institutional protocols to ensure safe delivery.

Serious risks include tendon rupture or inflammation, QT interval prolongation leading to cardiac arrhythmias, severe hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, seizures, and peripheral neuropathy. Patients should be monitored closely for any of these events, especially if they have pre‑existing risk factors.

Levofloxacin is contraindicated in individuals with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation. It should also be avoided in patients with a history of tendon disorders related to fluoroquinolone use, uncontrolled arrhythmias, or those taking medications that significantly prolong the QT interval.